

GenCore Version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd

OM protein - protein search, using sw model

Run on: January 16, 2003, 16:34:37 : Search time 66.6 seconds
(without alignments)
28.011 Million cell updates/sec

Title: US-09-856-070-17

Perfect score: 69
Sequence: 1 FKEKEUMKKEKHL 14

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 131250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- 1: /SID52/qcqlata/geneseq/geneseq-emb1/AA1980.DAT: *
- 2: /SID52/qcqlata/geneseq/geneseq-emb1/AA1981.DAT: *
- 3: /SID52/qcqlata/geneseq/geneseq-emb1/AA1982.DAT: *
- 4: /SID52/qcqlata/geneseq/geneseq-emb1/AA1983.DAT: *
- 5: /SID52/qcqlata/geneseq/geneseq-emb1/AA1984.DAT: *
- 6: /SID52/qcqlata/geneseq/geneseq-emb1/AA1985.DAT: *
- 7: /SID52/qcqlata/geneseq/geneseq-emb1/AA1986.DAT: *
- 8: /SID52/qcqlata/geneseq/geneseq-emb1/AA1987.DAT: *
- 9: /SID52/qcqlata/geneseq/geneseq-emb1/AA1988.DAT: *
- 10: /SID52/qcqlata/geneseq/geneseq-emb1/AA1989.DAT: *
- 11: /SID52/qcqlata/geneseq/geneseq-emb1/AA1990.DAT: *
- 12: /SID52/qcqlata/geneseq/geneseq-emb1/AA1991.DAT: *
- 13: /SID52/qcqlata/geneseq/geneseq-emb1/AA1992.DAT: *
- 14: /SID52/qcqlata/geneseq/geneseq-emb1/AA1993.DAT: *
- 15: /SID52/qcqlata/geneseq/geneseq-emb1/AA1994.DAT: *
- 16: /SID52/qcqlata/geneseq/geneseq-emb1/AA1995.DAT: *
- 17: /SID52/qcqlata/geneseq/geneseq-emb1/AA1996.DAT: *
- 18: /SID52/qcqlata/geneseq/geneseq-emb1/AA1997.DAT: *
- 19: /SID52/qcqlata/geneseq/geneseq-emb1/AA1998.DAT: *
- 20: /SID52/qcqlata/geneseq/geneseq-emb1/AA1999.DAT: *
- 21: /SID52/qcqlata/geneseq/geneseq-emb1/AA2000.DAT: *
- 22: /SID52/qcqlata/geneseq/geneseq-emb1/AA2001.DAT: *
- 23: /SID52/qcqlata/geneseq/geneseq-emb1/AA2002.DAT: *

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query No.	Score	Match	Length	DB ID	Description
1	69	100.0	14	23	AA882035	Human hepreceptor
2	69	100.0	436	23	AA871954	Human colon cancer
3	69	100.0	586	20	AA274443	Amino acid sequence
4	69	100.0	522	22	AA030004	Novel human secret
5	69	100.0	635	21	AA853356	Human colon cancer
6	51	73.9	503	22	AA816577	Novel human diango
7	51	73.9	593	22	ABG19947	Novel human diango
8	49	71.0	52	22	AA033060	Novel human secret
9	47	68.1	357	22	AA016454	Human novel secret
10	47	68.1	472	22	AA016019	Human novel secret

11	47	68.1	484	21	AA842228	Human GREX ORF1992
12	47	68.1	580	22	AA842158	Human polypeptide
13	47	68.1	580	22	AA842159	Human polypeptide
14	47	68.1	690	22	AA895603	Human protein sequ
15	47	68.1	691	22	AA840372	Human polypeptide
16	47	68.1	691	22	AA012179	Human PRO4996 poly
17	47	68.1	691	23	AA807265	Human APRC polypep
18	47	68.1	711	22	AA840373	Human polypeptide
19	47	68.1	1072	22	AA870871	C albicans apoptos
20	47	68.1	2274	22	AA870871	C albicans apoptos
21	46	66.7	75	23	ABP31093	Human ORF66 protei
22	46	66.7	586	22	AA012194	Human PRO4987 poly
23	46	66.7	586	23	AAH77445	Human tumour marke
24	46	66.7	586	23	AAH97317	Novel human protei
25	46	66.7	633	19	AA848892	Human quanylate bi
26	46	66.7	721	22	AB862213	Leucophila melanoq
27	45	65.2	222	22	ABG08101	Novel human diango
28	44	63.8	374	21	AA829389	Arabidopsis thalia
29	44	63.8	793	22	AAH76980	Human inverted DCA
30	43	62.3	87	22	AA894328	Human reproductive
31	43	62.3	87	22	AA016587	Human novel secret
32	43	62.3	98	22	AA821483	Peptide #7917 enco
33	43	62.3	98	22	AA837734	Peptide #11771 enc
34	43	62.3	98	23	AA846577	Human peptide enco
35	43	62.3	121	22	AA016172	Human novel secret
36	43	62.3	179	22	AA874288	Human colon cancer
37	43	62.3	289	22	AA893619	Human protein sequ
38	43	62.3	301	8	AA870867	Sequence of acidic
39	43	62.3	354	21	AA842527	Human GREX ORF2291
40	43	62.3	354	22	AAH71628	Leucophila melanoq
41	43	62.3	513	22	AA842356	Human polypeptide
42	43	62.3	513	22	AA895321	Human protein sequ
43	43	62.3	533	22	AA863463	Human cell cycle a
44	43	62.3	567	22	AA813147	Human retinilis pi
45	43	62.3	740	13	AA875736	Plasmodium falcipa

ALIGNMENTS

RESULT 1

AA882035

ID AA882035 standard, peptide: 14 AA.

XX AA882035;

XX 13-JUN-2001 (first entry)

XX Human hepreceptor domain A/H binding peptide Rucp1024.

XX Human, hepreceptor; cytosolic, anti-HIV, antibiotic;

XX oncogenic, immune response inducer, ezrin; infectious diseases: cancer;

XX HIV-related dementia.

XX Homo sapiens.

XX GB3354241-A.

XX 21-MAR-2001.

XX 17-SEP-1999; 99GB-0021881.

XX 17-SEP-1999; 99GB-0021881.

XX (HOLM/) HOLMS R D.

XX Holms RD;

XX WPI: 2001 293287/31

XX Novel regulatory or scaffolding peptides of ezrin that binds to

XX hepreceptor; useful for inducing immune response for treating

XX infectious diseases and cancer .

XX PS Claim 20; Page 36; 42pp; English.

XX CC The hepreceptor is a novel active site in human ezrin. Ezrin regulates

XX CC the structure of the cortical cytoskeleton to control cell surface

XX CC topography. The present invention relates to peptides (see AAB82021 to

XX CC AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see

XX CC AAB82046). The hepreceptor binding peptides are useful for inducing

XX CC immune response, and for treating infectious diseases, cancer and

XX CC HIV-related dementia. The present invention binds to domains A and B of the

XX CC hepreceptor (AAB82019 and AAB82020).

XX SQ Sequence 14 AA:

Query Match 100.0%; Score 69; DH 22; Length 14;

Best Local Similarity 100.0%; Pred. No. 0.00073;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EREKEQMMREKEEL 14

DB 1 EREKEQMMREKEEL 14

RESULT 2

AAG73954

1b AAG73954 standard; Protein: 436 AA.

XX AC AAG73954;

XX DT 03-SEP-2001 (first entry)

XX DE Human colon cancer antigen protein SEQ ID NO:4718.

XX KW Human; colon cancer; colon cancer antigen; diagnosis; detection;

XX KW colorectal carcinoma.

XX OS Homo sapiens.

XX PN WO200122920 A2.

XX PD 05-APR-2001.

XX PF 28-SEP-2000; 2000WO-US-6524.

XX PR 29-SEP-1999; 99US-0157137.

XX PR 03-NOV-1999; 99US-0163280.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PI Ruben SM, Barash SC, Birse CE, Rosen CA;

XX DR WPI; 2001-245357/24.

XX DR N-PSDB; AAB33385.

XX PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides,

XX PT useful for preventing, diagnosing and/or treating colorectal cancers.

XX PS Claim 11; Page 6520-6521; 9803pp; English.

XX CC AAB32043 to AAB37195 and AAB37514 to AAB37788 represent human colon

XX CC cancer-associated nucleic acid molecules (N) and proteins (P), where

XX CC the proteins are collectively known as colon cancer antigens. The colon

XX CC cancer antigens have cytostatic activity and can be used in gene

XX CC therapy and vaccine production. N and P may be used in the prevention,

XX CC diagnosis and treatment of diseases associated with inappropriate P

XX CC expression. For example, N and P may be used to treat disorders

XX CC associated with decreased expression by rectifying mutations or deletions

XX CC in a patient's genome that affect the activity of P by expressing

XX CC inactive proteins or to supplement the patients own production of P.

XX CC Additionally, N may be used to produce the colon cancer-associated PS,

XX CC by inserting the nucleic acids into a host cell and culturing the cell

XX CC to express the proteins. N and P can be used in the prevention, diagnosis

XX CC and treatment of colorectal carcinomas and cancers AAB37196 to AAB37204

CC and AAB37789 represent sequences used in the exemplification of the

CC present invention.

CC N & pages 665 to 682 and page 7053 of the sequence listing were

CC missing at time of publication, meaning no sequences are present for

XX SEQ ID NO:1027 to 1052, 7921 and 7922.

XX SQ Sequence 436 AA;

Query Match 100.0%; Score 69; DH 22; Length 446;

Best Local Similarity 100.0%; Pred. No. 0.024;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EREKEQMMREKEEL 14

DB 184 EREKEQMMREKEEL 197

RESULT 3

AAV27443

ID AAV27443 standard; Protein: 586 AA.

XX AC AAV27443;

XX DT 26-NOV-1999 (first entry)

XX DE Amino acid sequence of human ezrin polypeptide.

XX KW Pharmaceutical; ezrin; mutant; tumor; metastasis; human.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT Misc difference 354

FT /note- "the Tyr at this position can be mutated

FT (preferably to a Phe) to construct an

FT ezrin mutant of the invention"

XX PN WO9947150-A2.

XX PD 23-SEP-1999.

XX PF 18-MAR-1999; 99WO-EP02054.

XX PR 18-MAR-1998; 98US-0040725

XX PA (CURT-) INST CURIE.

XX PA (CNRS) CNRS CENT NAT RECH SCI.

XX PI Arpin M, Crepaldi T, Gautreau A, Louvard D;

XX DR WPI; 1999-561851/47.

XX PT New composition for prevention and treatment of tumors and metastasis

XX PS Example 1; Fig 1; 31pp; English.

XX CC The invention provides a pharmaceutical composition containing ezrin

XX CC protein, RNA or DNA mutated on tyrosine 353, or a functional fragment

XX CC or derivative of the ezrin mutant. The new composition is useful for

XX CC prevention and/or treatment of tumors, and especially metastasis. The

XX CC present sequence represents the amino acid sequence of human ezrin

XX CC (before the mutation by deletion of the first amino acid Met).

XX SQ Sequence 586 AA;

Query Match 100.0%; Score 69; DH 20; Length 586;

Best Local Similarity 100.0%; Pred. No. 0.033;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EREKEQMMREKEEL 14

DB 334 EREKEQMMREKEEL 347

```

RESULT 4
AAU30004
ID AAU30004 standard; Protein: 622 AA.
XX
AC AAU30004;
XX
DT 18-DEC-2001 (first entry)
XX
DE Novel human secreted protein #495.
XX
KW Human, vaccination; gene therapy; nutritional supplement;
KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;
KW immune suppression, immune stimulation, anti inflammatory, leukaemia.
XX
OS Homo sapiens.
XX
PN WO200174449-A2
XX
DT 25-OCT-2001.
XX
PF 16-APR-2001; 2001WO-US08656.
XX
PP 18-APR-2000; 2000US 0552929.
PR 26-JAN-2001; 2001US-0770160.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT,
XX
DR WPI: 2001-611725/70.
XX
PT Nucleic acids encoding a range of human polypeptides, useful in genetic
PT vaccination, testing and therapy -
XX
PS Claim 20, Page 219; 765pp, English.
XX
CC The invention relates to novel human secreted polypeptides. The
CC polypeptides and antibodies to the polypeptides are useful for
CC determining the presence of or predisposition to a disease associated
CC with altered levels of polypeptide. The polypeptides are also useful for
CC identifying agents (agonists and antagonists) that bind to them. Cells
CC expressing the proteins are useful for identifying a therapeutic agent
CC for use in treatment of a pathology related to aberrant expression or
CC physiological interactions of the polypeptide. Vectors comprising
CC the nucleic acids encoding the polypeptides and cells genetically
CC engineered to express them are also useful for producing the proteins.
CC The proteins are useful in genetic vaccination, testing and
CC therapy, and can be used as nutritional supplements. They may be used to
CC increase stem cell proliferation; to regulate haematopoiesis; and in
CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
CC immune suppression and/or stimulation; as anti-inflammatory agents; and
CC in treatment of leukaemias. AAU29510-AAU33304 represent the amino acid
CC sequences of novel human secreted proteins of the invention.
XX
SQ Sequence 622 AA;
Query Match 100.0%; Score 69; DR 22; Length 622;
Best Local Similarity 100.0%; Pred. No. 0.035;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EREKQMMPEKEEL 14
Db 370 EREKQMMPEKEEL 383
RESULT 5
AAB53356
ID AAB53356 standard; Protein: 635 AA
XX
AC AAB53356;
XX
DE Novel human diagnostic protein #16568.
XX
DT 09-MAR-2001 (first entry)
XX
DE Human colon cancer antigen protein sequence SEQ ID NO:896.
XX
KW Human; colon cancer; colon cancer antigen, diagnosis; detection;
KW identification, cytostatic; cardioactive; neuroprotective; vulnerary;
KW immunomodulatory; muscular; gynaecological; gastrointestinal;
KW nephrotropic; antiinfective; antibacterial; gene therapy; wound;
KW neural disorder; immune system disorder; muscular disorder;
KW reproductive disorder; gastrointestinal disorder; renal disorder;
KW infectious disease; cardiovascular disorder.
XX
OS Homo sapiens.
XX
PN WO200055351-A1.
XX
DT 21-SEP-2000.
XX
PF 08 MAR 2000; 2000WO US05883.
XX
PP 12-MAR-1999; 99US-0124270.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Posen CA, Ruben SM;
XX
DR WPI: 2000-587534/55
DR N-PSDB: AAC98113.
XX
PT Colon cancer associated gene sequences, referred to as colon cancer
PT antigens, useful for the treatment, prevention, and diagnosis of colon
PT disorders such as colon cancer -
XX
PS Claim 11, Page 1449-1451, 2104pp; English.
XX
CC AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC called human colon cancer antigens, given in AAB53234 to AAB54006. The
CC human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC vulnerary, nephrotropic, antiinfective and antibacterial activities, and
CC can be used in gene therapy. The colon cancer antigen polynucleotides,
CC proteins and antibodies to the proteins are useful for the prevention,
CC treatment and diagnosis of colon disorders, such as colon cancer. The
CC polynucleotides may be used in diagnostics and research, such as for
CC chromosome identification, and as hybridisation probes. The proteins
CC may also be used to prevent diseases such as neural disorders, immune
CC system disorders, muscular disorders, reproductive disorders,
CC gastrointestinal disorders, wounds, renal disorders, infectious
CC diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC AAB54007 represent sequences used in the exemplification of the present
CC invention.
XX
SQ Sequence 635 AA;
Query Match 100.0%; Score 69; DR 21; Length 635;
Best Local Similarity 100.0%; Pred. No. 0.036;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EREKQMMPEKEEL 14
Db 383 EREKQMMPEKEEL 396
RESULT 6
ABG16577
ID ABG16577 standard; Protein: 503 AA.
XX
AC ABG16577;
XX
DT 18 FEB 2002 (first entry)
XX
DE Novel human diagnostic protein #16568.
XX

```

KW Human: chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX
 OS Homo sapiens.
 XX
 FN WO200175067-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-0508631.
 XX
 PR 31-MAR-2000; 2000US-0540217.
 XX
 PR 23-AUG-2000; 2000US-0649167.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Drmanac RT, Liu C, Tang YT;
 XX
 PI WPI: 2001-639362/73.
 XX
 DR N-PSDB: AAS80764.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity.
 XX
 PS Claim 20: SEQ ID No 46936; 103pp; English.
 XX
 CC The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG3037 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.

.. SQ Sequence 503 AA;
 Query Match 73.9%; Score 51; DH 22; Length 503;
 Best Local Similarity 71.4%; Pred. No. 11;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 EREKQMMREKEEL 14
 I:||||:|||||
 Db 254 EREKTEREKEEL 267

RESULT 7
 AAG19947
 ID AAG19947 standard; Protein: 593 AA.
 XX
 AC AAG19947;
 XX
 DT 18 FEB-2002 (first entry)
 XX
 DE Novel human diagnostic protein #19938.

KW Human: chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.

XX
 OS Homo sapiens.
 XX
 FN WO200175067-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-0508631.
 XX
 PR 31-MAR-2000; 2000US-0540217.
 XX
 PR 23-AUG-2000; 2000US-0649167.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Drmanac RT, Liu C, Tang YT;
 XX
 PI WPI: 2001-639362/73.
 XX
 DR N-PSDB: AAS84134.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity.
 XX
 PS Claim 20: SEQ ID No 50306; 103pp; English.
 XX
 CC The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG3037 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.

.. SQ Sequence 593 AA;

Query Match 73.9%; Score 51; DH 22; Length 593;
 Best Local Similarity 71.4%; Pred. No. 13;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 EREKQMMREKEEL 14
 I:||||:|||||
 Db 349 EREKTEREKEEL 362

RESULT 8
 AAU33060
 ID AAU33060 standard; Protein: 52 AA.
 XX
 AC AAU33060;
 XX
 DT 18-DEC-2001 (first entry)
 XX
 DE Novel human secreted protein #3551.

KW Human: vaccination; gene therapy; nutritional supplement;
 KW stem cell proliferation; hematopoiesis; nerve tissue regeneration;
 KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
 XX

OS Homo sapiens.
 XX AAU16454 standard; Protein: 357 AA.
 PN WO200179449-A2
 XX 25-OCT-2001.
 PD
 XX
 PF 16-APR-2001; 2001WO-US01341.
 XX
 PF 04-FEB-2000; 2000US-0179065.
 XX
 PF 04-FEB-2000; 2000US-0180628.
 PR 24-FEB-2000; 2000US-0184664.
 PR 02-MAR-2000; 2000US-0186350.
 XX
 PR 16-MAR-2000; 2000US-0189874.
 PR 17-MAR-2000; 2000US-0190076.
 PR 18-APR-2000; 2000US-0198123.
 PR 19-MAY-2000; 2000US-0205515.
 PR 07-JUN-2000; 2000US-0209467.
 PR 24-JUN-2000; 2000US-0214886.
 PR 30-JUN-2000; 2000US-0215135.
 PR 07-JUL-2000; 2000US-0216647.
 PR 07-JUL-2000; 2000US-0216880.
 PR 11-JUL-2000; 2000US-0217487.
 PR 11-JUL-2000; 2000US-0217496.
 PR 14-JUL-2000; 2000US-0218290.
 PR 26-JUL-2000; 2000US-0220964.
 PR 26-JUL-2000; 2000US-0224518.
 PR 14-AUG-2000; 2000US-0224519.
 PR 14-AUG-2000; 2000US-0225213.
 PR 14-AUG-2000; 2000US-0225214.
 PR 14-AUG-2000; 2000US-0225266.
 PR 14-AUG-2000; 2000US-0225267.
 PR 14-AUG-2000; 2000US-0225268.
 PR 14-AUG-2000; 2000US-0225270.
 PR 14-AUG-2000; 2000US-0225447.
 PR 14-AUG-2000; 2000US-0225757.
 PR 14-AUG-2000; 2000US-0225758.
 PR 14-AUG-2000; 2000US-0225759.
 PR 18-AUG-2000; 2000US-0226279.
 PR 22-AUG-2000; 2000US-0226981.
 PR 22-AUG-2000; 2000US-0227182.
 PR 23-AUG-2000; 2000US-0227009.
 PR 30-AUG-2000; 2000US-0228924.
 PR 01-SEP-2000; 2000US-0229287.
 PR 01-SEP-2000; 2000US-0229343.
 PR 01-SEP-2000; 2000US-0229344.
 PR 01-SEP-2000; 2000US-0229345.
 PR 05-SEP-2000; 2000US-0229509.
 PR 05-SEP-2000; 2000US-0229513.
 PR 06-SEP-2000; 2000US-0230437.
 PR 06-SEP-2000; 2000US-0230438.
 PR 08-SEP-2000; 2000US-0231242.
 PR 08-SEP-2000; 2000US-0231243.
 PR 08-SEP-2000; 2000US-0231244.
 PR 08-SEP-2000; 2000US-0231413.
 PR 08-SEP-2000; 2000US-0231414.
 PR 08-SEP-2000; 2000US-0232080.
 PR 08-SEP-2000; 2000US-0234081.
 PR 12-SEP-2000; 2000US-0234968.
 PR 14-SEP-2000; 2000US-0234971.
 PR 14-SEP-2000; 2000US-0234981.
 PR 14-SEP-2000; 2000US-0234982.
 PR 14-SEP-2000; 2000US-0234983.
 PR 14-SEP-2000; 2000US-0234984.
 PR 14-SEP-2000; 2000US-0234985.
 PR 21-SEP-2000; 2000US-0234986.
 PR 21-SEP-2000; 2000US-0234987.
 PR 25-SEP-2000; 2000US-0234997.
 PR 25-SEP-2000; 2000US-0234998.
 PR 26-SEP-2000; 2000US-0235484.
 PR 27-SEP-2000; 2000US-0235834.
 PR 27-SEP-2000; 2000US-0235835.
 PR

Query March 71.08; Score 49; PR 22; Length 52;
 Host local similarity 100.0%; Prod No. 2;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 27 5 EQMMPEKEEL 14
 1111111111
 Db 6 EQMMPEKEEL 15

RESULT 9
 AAU16454
 ID AAU16454 standard; Protein: 357 AA.
 XX
 AC AAU16454;
 XX
 DT 07-NOV-2001 (first entry)
 XX
 DE Human novel secreted protein, Seq ID: 1407.
 XX
 KW Human; immunosuppressive; antiarthritic; antineoplastic;
 KW osteostatic; cardiac; anorectic; neuroprotective; neotropic;
 KW neuroprotective; anti-epileptic; virucide; fungicide; pharmacological;
 KW pulmonary; secreted protein; rheumatoid arthritis;
 KW hepatoprotective; also; neurovascular; also; cardiac arrest;
 KW cerebrovascular disorder; cerebral ischaemia; angiogenesis;
 KW nervous system disorder; Alzheimer's disease; infection; ocular disorder;
 KW corneal infection; wound healing; epithelial cell proliferation;
 KW skin ageing; food additive; preservative; anti-proliferative;
 XX Homo sapiens.
 XX

The invention relates to novel human secreted polypeptides. The polypeptides and antibodies to the polypeptides are useful for determining the presence of or predisposition to a disease associated with altered levels of polypeptides. The polypeptides are also useful for identifying agents (agonists and antagonists) that bind to them. Cells expressing the proteins are useful for identifying a therapeutic agent for use in treatment of a pathology related to aberrant expression or physiological interactions of the polypeptide. Vectors comprising the nucleic acids encoding the polypeptides and cells genetically engineered to express them are also useful for producing the proteins. The proteins are useful in genetic vaccination, testing and therapy, and can be used as nutritional supplements. They may be used to increase stem cell proliferation; to regulate haematopoiesis; and in bone, cartilage, tendon and/or native tissue growth or regeneration; immune suppression and/or stimulation; as anti-inflammatory agents; and in treatment of leukemias. AAU9510-AAU1404 represent the amino acid sequences of novel human secreted proteins of the invention.

Nucleic acids encoding a range of human polypeptides, useful in genetic vaccination, testing and therapy -
 Claim 20, Page 702, 76pp; English

PK 04-FEB-2000: 2000US-0180629
 PK 24-FEB-2000: 2000US-0184564
 PP 02-MAR-2000: 2000US-0186359
 PR 16-MAR-2000: 2000US-0186874
 PR 17-MAR-2000: 2000US-0190076
 PK 18-APR-2000: 2000US-0198124
 PR 19-MAY-2000: 2000US-0205515
 PR 07-JUN-2000: 2000US-0209457
 PR 28-JUN-2000: 2000US-0214085
 PP 30-JUN-2000: 2000US-0215135
 PP 07-JUL-2000: 2000US-0216647
 PP 07-JUL-2000: 2000US-0216880
 PP 11-JUL-2000: 2000US-0217487
 PR 11-JUL-2000: 2000US-0217495
 PR 14-JUL-2000: 2000US-0218260
 PP 26-JUL-2000: 2000US-0220964
 PP 26-JUL-2000: 2000US-0220964
 PR 14-AUG-2000: 2000US-0223454
 PR 14-AUG-2000: 2000US-0224519
 PP 14-AUG-2000: 2000US-0225213
 PP 14-AUG-2000: 2000US-0225214
 PP 14-AUG-2000: 2000US-0225274
 PP 14-AUG-2000: 2000US-0225277
 PR 14-AUG-2000: 2000US-0225447
 PR 14-AUG-2000: 2000US-0225757
 PP 14-AUG-2000: 2000US-0225758
 PP 14-AUG-2000: 2000US-0225759
 PR 22-AUG-2000: 2000US-0226279
 PR 22-AUG-2000: 2000US-0226281
 PP 22-AUG-2000: 2000US-0226868
 PP 22-AUG-2000: 2000US-0227182
 PP 23-AUG-2000: 2000US-0227099
 PP 30-AUG-2000: 2000US-0228924
 PP 01-SEP-2000: 2000US-0229287
 PP 01-SEP-2000: 2000US-0229444
 PP 01-SEP-2000: 2000US-0229444
 PP 01-SEP-2000: 2000US-0229444
 PP 05-SEP-2000: 2000US-0229509
 PP 05-SEP-2000: 2000US-0229513
 PR 06-SEP-2000: 2000US-0230042
 PR 06-SEP-2000: 2000US-0230048
 PR 08-SEP-2000: 2000US-0231242
 PP 08-SEP-2000: 2000US-0231243
 PR 08-SEP-2000: 2000US-0231244
 PR 08-SEP-2000: 2000US-0231414
 PR 08-SEP-2000: 2000US-0231414
 PP 08-SEP-2000: 2000US-0232080
 PP 08-SEP-2000: 2000US-0232081
 PP 12-SEP-2000: 2000US-0231968
 PR 14-SEP-2000: 2000US-0232307
 PR 14-SEP-2000: 2000US-0232308
 PR 14-SEP-2000: 2000US-0232309
 PR 14-SEP-2000: 2000US-0232309
 PR 14-SEP-2000: 2000US-0232403
 PP 14-SEP-2000: 2000US-0232403
 PR 14-SEP-2000: 2000US-0232404
 PR 14-SEP-2000: 2000US-0232404
 PR 21-SEP-2000: 2000US-0232423
 PR 21-SEP-2000: 2000US-0232423
 PR 25-SEP-2000: 2000US-0234274
 PR 25-SEP-2000: 2000US-0234274
 PR 25-SEP-2000: 2000US-0234498
 PP 26-SEP-2000: 2000US-0235484
 PP 27-SEP-2000: 2000US-0235834
 PR 29-SEP-2000: 2000US-0235836
 PR 29-SEP-2000: 2000US-0236327
 PP 29-SEP-2000: 2000US-0236327
 PP 29-SEP-2000: 2000US-0236369
 PP 29-SEP-2000: 2000US-0236370
 PR 02-OCT-2000: 2000US-0236802
 PR 02-OCT-2000: 2000US-0237037

PR 02-OCT-2000: 2000US-0237038
 PR 02-OCT-2000: 2000US-0237039
 PR 02-OCT-2000: 2000US-0237040
 PP 13-OCT-2000: 2000US-0239935
 PP 13-OCT-2000: 2000US-0239937
 PP 20-OCT-2000: 2000US-0249260
 PR 20-OCT-2000: 2000US-0241221
 PP 20-OCT-2000: 2000US-0241785
 PP 20-OCT-2000: 2000US-0241786
 PP 20-OCT-2000: 2000US-0241787
 PR 20-OCT-2000: 2000US-0241808
 PR 20-OCT-2000: 2000US-0241809
 PR 20-OCT-2000: 2000US-0241826
 PP 03-NOV-2000: 2000US-0244617
 PR 08-NOV-2000: 2000US-0246474
 PP 08-NOV-2000: 2000US-0246475
 PP 08-NOV-2000: 2000US-0246476
 PP 08-NOV-2000: 2000US-0246477
 PR 08-NOV-2000: 2000US-0246478
 PR 08-NOV-2000: 2000US-0246523
 PP 08-NOV-2000: 2000US-0246524
 PP 08-NOV-2000: 2000US-0246525
 PP 08-NOV-2000: 2000US-0246526
 PR 08-NOV-2000: 2000US-0246527
 PP 08-NOV-2000: 2000US-0246528
 PR 08-NOV-2000: 2000US-0246532
 PP 08-NOV-2000: 2000US-0246609
 PP 08-NOV-2000: 2000US-0246610
 PP 08-NOV-2000: 2000US-0246611
 PP 08-NOV-2000: 2000US-0246613
 PR 17-NOV-2000: 2000US-0249207
 PR 17-NOV-2000: 2000US-0249208
 PP 17-NOV-2000: 2000US-0249209
 PP 17-NOV-2000: 2000US-0249210
 PR 17-NOV-2000: 2000US-0249211
 PR 17-NOV-2000: 2000US-0249212
 PP 17-NOV-2000: 2000US-0249213
 PP 17-NOV-2000: 2000US-0249214
 PP 17-NOV-2000: 2000US-0249215
 PR 17-NOV-2000: 2000US-0249216
 PR 17-NOV-2000: 2000US-0249217
 PR 17-NOV-2000: 2000US-0249218
 PR 17-NOV-2000: 2000US-0249244
 PR 17-NOV-2000: 2000US-0249244
 PR 17-NOV-2000: 2000US-0249264
 PP 17-NOV-2000: 2000US-0249265
 PR 17-NOV-2000: 2000US-0249297
 PR 17-NOV-2000: 2000US-0249299
 PR 17-NOV-2000: 2000US-0249300
 PR 31-DEC-2000: 2000US-0250160
 PP 31-DEC-2000: 2000US-0250491
 PR 31-DEC-2000: 2000US-0251030
 PR 05-DEC-2000: 2000US-0251988
 PP 05-DEC-2000: 2000US-0256719
 PR 05-DEC-2000: 2000US-0251479
 PP 09-DEC-2000: 2000US-0251856
 PP 09-DEC-2000: 2000US-0251869
 PR 09-DEC-2000: 2000US-0251869
 PR 09-DEC-2000: 2000US-0251989
 PR 09-DEC-2000: 2000US-0251990
 PR 11-DEC-2000: 2000US-0254097
 PP 05-JAN-2001: 2001US-0259678

(HUMA-) HUMAN GENOME SCI INC.
 Rosen CA, Barash SC, Ruben SM,
 WPI, 2001-488783/53.
 N-PSGB, NAS2606
 New nucleic acid molecules encoding 461 human secreted proteins for
 diagnosing, preventing, treating or ameliorating medical conditions and
 used as food additives or preservatives -

XX Claim 11: SEQ ID NO 972: 980pp; English.

XX The invention relates to isolated nucleic acid molecules and their

XX encoded secreted proteins. The nucleic acids and proteins are used to

XX prevent, treat or ameliorate a medical condition in e.g. humans, mice,

XX rabbits, goats, horses, cats, dogs, chickens or sheep. They

XX are also used in diagnosing a pathological condition or susceptibility

XX to a pathological condition. Antibodies to the proteins can also

XX be used in alleviating symptoms associated with the disorders and in

XX diagnostic immunoassays e.g. radioimmunoassays or enzyme linked

XX immunosorbent assays (ELISA). Disorders which are diagnosed or treated

XX include autoimmune diseases e.g. rheumatoid arthritis,

XX hyperproliferative disorders e.g. neoplasms of the breast or liver,

XX cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders

XX e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g.

XX Alzheimer's disease, infections caused by bacteria, viruses and fungi

XX and ocular disorders e.g. corneal infection, and many other

XX disorders listed in the specification. The polypeptides can also

XX be used to aid wound healing and epithelial cell proliferation, to

XX prevent skin aging due to sunburn, to maintain organs before

XX transplantation, for supporting cell culture of primary tissues, to

XX regenerate tissues and in chemotaxis. The polypeptides can also be used

XX as a food additive or preservative to increase or decrease storage

XX capabilities, fat content, lipid, protein, carbohydrate, vitamins,

XX minerals, cofactors and other nutritional components. The present

XX sequence represents a novel secreted protein of the invention.

Query Match 68.1%; Score 47; DB 22; Length 472,
Best Local Similarity 57.1%; Pred. No. 40;
Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0.

QY 1 EREKEQMMREKEEL 14

DE 188 QKEKEQLQEEKQEL 201

RESULT 11

AAB42228

ID AAB42228 standard; Protein, 484 AA.

AC AAB42228

XX 08-FEB-2001 (first entry)

XX Human ORFX OPF1992 polypeptide sequence SEQ ID NO:3984.

XX Human; open reading frame; ORFX; detection, cytostatic; hepatotropic;
XX vulnervary; antiproliferative; antiparkinsonian; neurotropic; neuroprotective;
XX anticonvulsant; osteopathic; antiarthritis; immunosuppressant; cardiac;
XX immunostimulant; thrombolytic; coagulant; vasoregulator; antidiabetic;
XX hypotensive; dermatological; immunosuppressive; antineoplastic;
XX antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
XX antianemic; gene therapy; cancer; proliferative disorder; hypertension;
XX neurodegenerative disorder; osteoarthritis; graft vs host disease;
XX cardiovascular disease, diabetes mellitus; hypothyroidism; SCID; AIDS;
XX cholesterol ester storage; systemic lupus erythematosus; infection;
XX severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
XX allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
XX bone damage; cartilage damage; antiinflammatory disease; coagulation;
XX thrombosis; contraceptive.

OS Homo sapiens

XX W0200058473-A2.

PN W0200058473-A2.

XX 05-OCT-2000.

XX 31-MAR-2000; 2000WO-US08621.

XX 31-MAR-1999; 9905-0127607.

XX 02-APR-1999; 9905-0127636.

XX 05-APR-1999; 9905-0127728.

PR 30-MAR-2000; 2000US-0540763.

XX (CURA-) CURAGEN CORP.

XX Shimkels RA, Leach M;

XX WPI: 2000-020362/57.

XX N-PSDB; AAC76437.

XX Novel nucleic acids and peptides derived from open reading frame X,
XX useful for treating e.g. cancers, proliferative disorders,
XX neurodegenerative disorders and cardiovascular disease -
XX Claim 11; Page 3150-3152; 5507pp, English.

XX AAC74446 to AAC7506 encode the proteins given in AAB40237 to AAB43397,
XX which represent the human ORFX open reading frames 1 to 461. The ORFX
XX sequences have activities such as: cytostatic; hepatotropic; vulnervary;
XX antiproliferative; antiparkinsonian; neurotropic; neuroprotective;
XX osteopathic; anticonvulsant; antiarthritis; immunosuppressant;
XX immunostimulant; cardiac; thrombolytic; coagulant; vasoregulator;
XX antidiabetic; hypotensive; dermatological; immunosuppressive;
XX antiinflammatory; antibacterial; antiviral; antifungal; antirheumatic;
XX antithyroid; and antianemic. The sequences can be used for determining
XX the presence of or predisposition to, or preventing or treating
XX pathological conditions associated with an ORFX-associated disorder. The
XX nucleic acids can be used to express ORFX proteins in gene therapy.
XX The proteins and nucleic acids may be used to treat cancers,
XX proliferative disorders, neurodegenerative disorders, osteoarthritis,
XX graft vs host disease, cardiovascular disease, diabetes mellitus,
XX hypertension, hypothyroidism, cholesterol ester storage, systemic lupus
XX erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,
XX bacterial or fungal infection, malaria, autoimmune disorders, asthma,
XX allergies, aplastic anaemia, burns, wounds, bone and cartilage damage,
XX nocturnal haemoglobinuria, antiinflammatory disease; to enhance
XX coagulation, to inhibit thrombosis; and as a contraceptive.

XX Sequence 484 AA;

Query Match 68.1%; Score 47; DB 21; Length 484;
Best Local Similarity 57.1%; Pred. No. 41;
Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1 EREKEQMMREKEEL 14

DE 276 QKEKEQLQEEKQEL 289

RESULT 12

AAM42158

ID AAM42158 standard; Protein, 580 AA.

XX AAM42158;

XX 23-OCT-2001 (first entry)

XX Human polypeptide SEQ ID NO 7089.

XX Human; neurotropic; immunosuppressant; cytostatic; gene therapy; cancer;
XX peripheral nervous system, neuropathy, central nervous system; CNS;
XX Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
XX amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
XX chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
XX leukaemia.

OS Homo sapiens.

XX W0200153312-A1.

XX 26-JUL-2001.

XX 26-JUL-2000; 2000WO-US34263.

PR 21-JAN-2000; 2000US-0488725.
 PP 25-APR-2000; 2000US-057317.
 PP 09-JUL-2000; 2000US-0598042.
 PP 19-JUL-2000; 2000US-0620310.
 PP 03-AUG-2000; 2000US-0654450.
 PP 14-SEP-2000; 2000US-0662101.
 PP 19-OCT-2000; 2000US-0684036.
 PP 29-NOV-2000; 2000US-0727344.
 XX (HYSE-) HYSEQ INC.
 XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX WPI: 2001-442253/47.
 DR N-PSDB; AA161314.
 XX Novel nucleic acids and polypeptides useful for treating disorders
 PT such as central nervous system injuries
 PS Example 2: SEQ ID NO 7089; 10078pp, English.
 XX The invention relates to human nucleic acids (AA157798-AA161369) and
 CC the encoded polypeptides (AA158642-AA162215) with nucleotide
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 XX Sequence 580 AA;
 SQ Query Match 68.1%; Score 47; DB 22; Length 580;
 Best Local Similarity 57.1%; Pred. No. 50;
 Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1 EREKQMMREKEEL 14
 DB 495 QREKEQLQREKEEL 508
 XX
 RESULT 13
 AA442159
 ID AA442159 standard; Protein: 580 AA.
 XX
 AC AA442159;
 DI 22-OCT-2001 (first entry)
 XX Human polypeptide SEQ ID NO 7090.
 DE
 XX Human, non replic, immunosuppressant, cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia.
 XX Homo sapiens.
 OS
 XX WO200153312-A1.
 PN 26-JUL-2001

XX 20 DEC 2000; 2000US-0541663.
 XX 31 JAN-2000; 2000US-0488725.
 XX 25 APR-2000; 2000US-0598042.
 XX 09-JUL-2000; 2000US-0620310.
 XX 19-JUL-2000; 2000US-0654450.
 XX 03-AUG-2000; 2000US-0662101.
 XX 14-SEP-2000; 2000US-0684036.
 XX 19-OCT-2000; 2000US-0727344.
 XX 29-NOV-2000; 2000US-0727344.
 XX (HYSE-) HYSEQ INC.
 XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX WPI: 2001-442253/47.
 DR N-PSDB; AA161315.
 XX Novel nucleic acids and polypeptides useful for treating disorders
 PT such as central nervous system injuries
 PS Example 2: SEQ ID NO 7090; 10078pp; English.
 XX The invention relates to human nucleic acids (AA157798-AA161369) and
 CC the encoded polypeptides (AA158642-AA162215) with nucleotide
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 XX Sequence 580 AA;
 SQ Query Match 68.1%; Score 47; DB 22; Length 580;
 Best Local Similarity 57.1%; Pred. No. 50;
 Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1 EREKQMMREKEEL 14
 DB 495 QREKEQLQREKEEL 508
 XX
 RESULT 14
 AA495603
 ID AA495603 standard; Protein: 690 AA.
 XX
 AC AA495603;
 DI 26-JUN-2001 (first entry)
 XX Human protein sequence SEQ ID NO.18294.
 DE
 XX Human, primet, detection, diagnosis, antisense therapy; gene therapy.
 KW human, primet, detection, diagnosis, antisense therapy; gene therapy.
 XX Homo sapiens.
 OS
 XX EP1074617-A2.
 PN 07-FEB-2001.
 XX 28-JUL-2000; 2000EP-0116136.

XX 29-JUL-1999; 99JP-0248036.
 PR 27-AUG-1999; 99JP-0300253.
 PR 11-JAN-2000; 2000JP 0118776.
 PR 02-MAY-2000; 2000JP-0183767.
 PR 09-JUN-2000; 2000JP-0241899.
 XX (HELIX) HELIX RES INST.
 PA Ota T, Isoqai T, Nishikawa T, Hayashi K, Saito K, Yamamoto T,
 PI Ishii S, Sudojama T, Wakamatsu A, Naito K, Otsuki T.
 XX WPI: 2001-318744/44
 XX primer sets for synthesizing polynucleotides, particularly the 5602
 PT full-length cDNAs defined in the specification, and for the detection
 PT and/or diagnosis of the abnormality of the proteins encoded by the
 PT full-length cDNAs.
 PS Claim 8; SEQ ID NO 18294; 2537pp + Cb ROM; English.
 XX The present invention describes primer sets for synthesizing 5602
 CC full-length cDNAs defined in the specification. Where a primer set
 CC comprises: (a) an oligo dT primer and an oligonucleotide complementary
 CC to the complementary strand of a polynucleotide which comprises one of
 CC the 5602 nucleotide sequences defined in the specification, where the
 CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
 CC of an oligonucleotide comprising a sequence complementary to the
 CC complementary strand of a polynucleotide which comprises a 5' end
 CC sequence and an oligonucleotide comprising a sequence complementary to a
 CC polynucleotide which comprises a 3' end sequence, where the
 CC oligonucleotide comprises at least 15 nucleotides and the combination of
 CC the 5' end sequence/3' end sequence is selected from those defined in
 CC the specification. The primer sets can be used in antisense therapy and
 CC in gene therapy. The primers are useful for synthesizing polynucleotides,
 CC particularly full-length cDNAs. The primers are also useful for the
 CC detection and/or diagnosis of the abnormality of the proteins encoded by
 CC the full-length cDNAs. The primers allow obtaining of the full-length
 CC cDNAs easily without any specialised methods. AAH1466 to AAH1928 and
 CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
 CC AAH95893 represent human amino acid sequences; and AAH13629 to AAH13632
 CC represent oligonucleotides, all of which are used in the exemplification
 CC of the present invention.
 XX Sequence 690 AA:
 SQ
 Query Match 68.1%; Score 47; DB 22; Length 690;
 Best Local Similarity 57.1%; Pred. No. 59;
 Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1 EREKQMMREKEEL 14
 Db 483 QREKEQLOEKEQEL 496
 EREKQMMREKEEL 14
 QREKEQLOEKEQEL 496
 HESULT 15
 AAH40472
 ID AAH40472 standard; Protein: 691 AA.
 AA 40472;
 AA 40472;
 XX 22 OCT-2001 (first entry)
 XX Human polypeptide SEQ ID NO 3517.
 XX Human; neotropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia.
 XX Homo sapiens.

XX WO200153312-A1.
 XX 26-JUL-2001.
 PD 26-JUL-2001; 2000WJ-US34263.
 XX 21-JAN-2000; 2000US-0488725.
 PR 25-APR-2000; 2000US-052317.
 PR 04-JUL-2000; 2000US-059842.
 PR 19-JUL-2000; 2000US-072942.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14 SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 20-NOV-2000; 2000US-0727344.
 XX (HYSE-) HYSEQ INC.
 XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian Xb, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX WPI: 2001-442253/47.
 PR N-PSDB; AA159528.
 XX Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries.
 XX Example 6; SEQ ID NO 3517; 10078pp; English.
 XX The invention relates to human nucleic acids (AA157798-AA161369) and
 CC the encoded polypeptides (AAH48642-AAH42213) with neotropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 XX Sequence 691 AA;
 SQ
 Query Match 68.1%; Score 47; DB 22; Length 691;
 Best Local Similarity 57.1%; Pred. No. 59;
 Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1 EREKQMMREKEEL 14
 Db 483 QREKEQLOEKEQEL 496
 EREKQMMREKEEL 14
 QREKEQLOEKEQEL 496
 Search completed: January 16, 2003, 16:49:12
 Job time : 67.6 secs